<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta http-equiv="X-UA-Compatible" content="ie=edge">
  <title>Project VasCura CDE4301</title>
  <link rel="icon" href="./favicon.ico" type="image/x-icon">

  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@shoelace-style/shoelace@2.16.0/cdn/themes/light.css" />
  <script type="module"
    src="https://cdn.jsdelivr.net/npm/@shoelace-style/shoelace@2.16.0/cdn/shoelace-autoloader.js"></script>

  <link rel="stylesheet" href="./index.css">

  <link rel="stylesheet" href="./components/team-member/team-member.css">
  <script type="module" src="./components/team-member/team-member.js"></script>

  <link rel="stylesheet" href="./components/table-of-content/table-of-content.css">

  <script type="module" src="./components/image/image-component.js"></script>

  <script type="module" src="./components/video/video.js"></script>

  <link rel="stylesheet" href="./components/references/references.css">

  <link rel="stylesheet" href="./components/scroll-to-top/scroll-to-top.css">
  <script src="./components/scroll-to-top/scroll-to-top.js"></script>

  <script src="./components/table-component/table-component.js"></script>

  <link href="https://unpkg.com/gridjs/dist/theme/mermaid.min.css" rel="stylesheet" />
</head>

<body>
  <div class="content">
    <h1>VasCura</h1>
    <p style="text-align: center; font-size: 1.05rem; font-style: italic; color: #555; margin-top: -10px;">A Novel Mechanical Approach to Prolong Arteriovenous Fistula Patency</p>

    <!-- This is the team member component use to display details about your team members -->
    <div class="team-member-wrapper">

      <team-member avatar="assets/Potrait_ver2.jpg" name="Amelia Ong" department="NUS Biomedical Engineering"
        year="2025"></team-member>
      <team-member avatar="assets/pinkranger.png" name="Lin Ming" department="Duke-NUS Medical School"
        year="2025"></team-member>
      <team-member avatar="assets/blueranger.png" name="Eliot Read" department="NUS Business"
        year="2025"></team-member>
    </div>

    <!-- This is a divide from the shoelace library for aesthetic purpose -->
    <sl-divider></sl-divider>

    <!-- This is the table-of-content component used to define links directly to each section -->
    <div class="table-of-content">
      <h2>Table of Contents</h2>
      <sl-tree>
        <sl-tree-item>
          <a href="#acknowledgement">Acknowledgement</a>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#list-of-common-acronyms">List of Common Acronyms</a>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#introduction">1. Introduction</a>
        </sl-tree-item>

        <sl-tree-item expanded>
          <a href="#background">2. Background</a>
          <sl-tree-item>
            <a href="#background-of-haemodialysis">2.1. Background of haemodialysis</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#vascular-access-types">2.2. Vascular Access types</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#current-standard-of-care">2.3. Current Standard of Care</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item expanded>
          <a href="#problem-clarification">3. Problem Clarification</a>
          <sl-tree-item>
            <a href="#burden-of-access-failure-and-impact">3.1. Burden of access failure and impact</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#stakeholder-interviews">3.2. Stakeholder analysis</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#reintervention-reasons">3.3. Reasons for high re-intervention rates</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#existing-solutions-and-limitations">3.4. Existing solutions and limitations</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#key-insights">3.5. Key Insights</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#need-statement">3.6. Need Statement</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#value-proposition">4. Value Proposition</a>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#design-methodology">5. Design methodology</a>
          <sl-tree-item>
            <a href="#jobs-to-be-done-pains-and-gains">5.1. Jobs-to-be-Done, Pains and Gains</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#initial-functional-analysis">5.2. Initial Functional Analysis</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#design-statement">6. Design Statement</a>
          <sl-tree-item>
            <a href="#design-specifications">6.1. Design specifications</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#concept-generation">6.2. Concept Generation</a>
            <sl-tree-item>
              <a href="#concept-1">6.2.1 Concept 1</a>
            </sl-tree-item>
            <sl-tree-item>
              <a href="#concept-2">6.2.2 Concept 2</a>
            </sl-tree-item>
            <sl-tree-item>
              <a href="#concept-3">6.2.1 Concept 3</a>
            </sl-tree-item>
            <sl-tree-item>
              <a href="#concept-4">6.2.1 Concept 4</a>
            </sl-tree-item>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#concept-selection">6.3. Concept Selection</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#concept-design">7. Concept Design</a>
          <sl-tree-item>
            <a href="#detailed-concept-design">7.1. Detailed Concept Design</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#prototyping">8. Prototyping</a>
          <sl-tree-item>
            <a href="#avf-model">8.1. AVF Model</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#thrombosis-stenosis-analogues">8.2. Thrombosis/Stenosis Analogues</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#prototyping-bench-testing-models">8.3. Prototyping/Bench testing models</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#future-work">9. Future work</a>
        </sl-tree-item>
      </sl-tree>
    </div>
    <sl-divider></sl-divider>

    <div>

      <!-- Acknowledgement Section -->
      <div id="acknowledgement">
        <h2>Acknowledgement</h2>
        <p>
          Add your acknowledgement text here.
        </p>
      </div>

      <!-- List of Common Acronyms Section -->
      <div id="list-of-common-acronyms">
        <h2>List of Common Acronyms</h2>
        <p>
          Add your acronyms list here.
        </p>
        <table style="width:100%; border-collapse: collapse; margin-bottom: 2em;">
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">HD</td>
            <td style="border: 1px solid #000; padding: 8px;">Haemodialysis</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">ESKD</td>
            <td style="border: 1px solid #000; padding: 8px;">End-stage kidney disease</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">AVF</td>
            <td style="border: 1px solid #000; padding: 8px;">Arteriovenous Fistulas</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">AVG</td>
            <td style="border: 1px solid #000; padding: 8px;">Arteriovenous Grafts</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">CVC</td>
            <td style="border: 1px solid #000; padding: 8px;">Central Venous Catheters</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">CC</td>
            <td style="border: 1px solid #000; padding: 8px;">Chronic Clots</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">NIH</td>
            <td style="border: 1px solid #000; padding: 8px;">Neo-intimal Hyperplasia</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">KDOQI</td>
            <td style="border: 1px solid #000; padding: 8px;">Kidney Disease Outcomes Quality Initiative</td>
          </tr>
        </table>
      </div>

      <!-- This is an example of what a section might look like -->
      <div id="introduction">

        <h2> 1. Introduction </h2>
        <p>
          This project, conducted with Singapore General Hospital (Vascular Surgery) and Becton Dickinson, aims to develop a device to restore arteriovenous fistula patency for patients on haemodialysis by addressing the root causes of access obstruction. This interim report summarises stakeholder insights, a focused literature review, gaps in current solutions, our concept generation, rationale, and early prototyping toward a durable, clinically impactful solution.
        </p>
      </div>

      <!-- Background Section -->
      <div id="background">
        <h2>2. Background</h2>
      </div>

      <div id="background-of-haemodialysis">
        <h3>2.1. Background of haemodialysis</h3>
        <p>
          Haemodialysis (HD) is an extracorporeal therapy that removes metabolic waste, excess salts, and water through a dialyser to maintain chemical balance and blood pressure when renal function falls below 10–15% [1]. End-stage kidney disease (ESKD) most commonly results from long-term complications of diabetes mellitus and hypertension [2]. During HD, blood is continuously withdrawn through an arterial needle, filtered across a semipermeable membrane, and returned via a venous needle. In Singapore and globally, in-centre HD is performed three times weekly for approximately four hours per session [1].
        </p>

        <image-component tag="dialysis" source="assets/dialysis schematic.jpg"
          subtitle="Figure 1. General schematic of dialysis [1]"></image-component>
      </div>

      <div id="vascular-access-types">
        <h3>2.2. Vascular Access types</h3>
        <p>
          All haemodialysis patients require a surgically created vascular access to allow safe and sustained blood
          flow for dialysis. Native veins are too small and fragile to handle high flow rates and repeated needle
          insertions, while arteries bleed excessively when punctured directly.
        </p>

        <p>
          The arteriovenous fistula (AVF) connects an artery to a vein, and is the preferred method. Over several weeks,
          arterial pressure remodels and strengthens the vein wall, enabling repeated cannulation and maintaining blood
          flow of 300–500 mL/min for efficient dialysis [3].
        </p>

        <p>
          Other access options, such as arteriovenous grafts (AVG) and central venous catheters (CVC), are used when
          AVF creation is not feasible. AVF remains the gold standard due to its superior long-term patency, lower
          infection rates, and reduced risk of thrombosis [4]. In Singapore, approximately 7,000 patients, or 75 percent
          of those on dialysis, rely on an AVF as their primary vascular access [5].
        </p>

        <!-- Figure 2: Arteriovenous Fistula schematic -->
        <image-component tag="avf" source="assets/AVF.jpg"
          subtitle="Figure 2. Schematic of Arteriovenous Fistula [6]"></image-component>

        <!-- This is an example of how you might use the image component -->
        <!-- Image 1 (iDP suggested pathway) removed as requested -->
      </div>
    </div>


    <br />
    <br />
    <sl-divider></sl-divider>
    <div>
      <div id="current-standard-of-care">
        <h3>2.3. Current Standard of Care</h3>
        <p>
          AVF failure clinically presents as a decline in blood flow or difficulty with cannulation during dialysis. These signs often indicate stenosis, the abnormal narrowing of a vessel, or thrombosis, the formation of an intraluminal clot that obstructs flow, as outlined in the Kidney Disease Outcomes Quality Initiative (KDOQI) vascular access guidelines [7].
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <!-- Using the requested image file from assets: 'AVF stenosed.jpg' -->
          <img src="assets/AVF stenosed.jpg" alt="AVF stenosed - schematic of stenosis and thrombosis" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 3. Schematic of Stenosis and Thrombosis</em></figcaption>
        </figure>
        <p>
          When this occurs, patients are referred to vascular specialists to restore AVF patency and flow. Although these interventions can re-establish flow, recurrent narrowing and clot formation are common, leading to patients needing multiple procedures over time.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/patient pathway.jpg" alt="Patient pathway - flowchart of AVF patency-restoration pathway" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 4. Flowchart of the AVF patency-restoration pathway</em></figcaption>
        </figure>
      </div>

      <div id="problem-clarification">
        <h2>3. Problem Clarification</h2>
      </div>

      <div id="burden-of-access-failure-and-impact">
        <h3>3.1. Burden of access failure and impact</h3>
        <p>
          In Singapore, over 9,000 people rely on haemodialysis (HD) for survival [8]. Local data show that about two-thirds
          of arteriovenous fistula (AVF) patients require another procedure at some point after their access is created, and
          studies report that one in two patients needs re-intervention within six months [9]. Each procedure brings another
          hospital visit, exposure to X-rays, added costs, and discomfort.
        </p>

        <p>
          With Singapore’s ageing population and around 2,000 new kidney-failure cases each year, the demand for access
          maintenance continues to grow. This not only strains healthcare resources but also leads to longer waiting times
          [10].
        </p>

        <p>
          Each AVF salvage procedure costs about SGD 8,000 in direct medical expenses including the operating suite, devices,
          imaging, and sedation, excluding indirect costs such as missed dialysis sessions, transport, and caregiver time
          (Appendix A). Collectively, these represent a substantial financial and emotional burden for both patients and the
          healthcare system.
        </p>
      </div>

      <div id="stakeholder-interviews">
        <h3>3.2. Stakeholder analysis</h3>
        <p>
          To validate these findings, we interviewed interventional specialists, dialysis nurses, and patients. Their
          insights revealed not only clinical inefficiencies but also user frustrations with current AVF treatments,
          underscoring the urgent need for a durable and workflow-efficient solution. Key stakeholder insights are
          summarised below and detailed in Appendix B.
        </p>

        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px;">Quotes</th>
              <th style="border:1px solid #000; padding:10px;">Problem</th>
              <th style="border:1px solid #000; padding:10px;">Needs</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">“Around 1 in 2 patients require repeat intervention within six months.” - Dr Tan</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Frequent loss of patency, resulting in repeated interventions and high long-term treatment burden for patients.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Clinicians require a durable and reliable solution that maintains vessel patency over time to support consistent dialysis access.</td>
            </tr>

            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">“Chronic organised thrombus remains difficult to clear.” - Dr Alfred, Dr Luke</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Incomplete clearance of chronic clots limits flow restoration and procedural efficiency.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Operators require an effective system that safely removes chronic wall-adherent thrombus.</td>
            </tr>

            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">“~80% of re-interventions are driven by neointimal hyperplasia.” - Dr Apoorva</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">High residual neointimal hyperplasia (NIH) post intervention leads to NIH-driven AVF narrowing.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Clinicians require safe treatment methods that reduce intimal hyperplasia recurrence and preserve vessel wall integrity.</td>
            </tr>

            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">“I had two interventions this year and it is so expensive.” - Mdm Tan</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">High financial and emotional burden due to frequent re-interventions.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Patients need a cost-effective and durable solution that reduces repeat interventions and lowers overall treatment cost.</td>
            </tr>

            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">“Sometimes even after intervention, cannulation is still difficult.” - Nurse Aung</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Ineffective thrombus clearance, leading to poor flow and difficult cannulation for dialysis.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Nurses require a reliable system that restores consistent access flow suitable for dialysis use.</td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:-1em; margin-bottom:1.5em;">Table 1. Stakeholder analysis</p>

      </div>

      <div id="reintervention-reasons">
        <h3>3.3. Reasons for high re-intervention rates</h3>
        <p>
          We conducted a root-cause analysis to understand why AVFs often fail despite repeated intervention to clear the blockage. Two main clusters emerged: factors outside the procedure, such as flow dynamics and vessel condition, and factors within the procedure, primarily the limitations of current devices.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/Root cause analysis.jpg" alt="Root cause analysis table" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 5. Root-cause analysis</em></figcaption>
        </figure>
        <p>
          After AVF creation, turbulent flow and repeated needle punctures promote the formation of clots and neointimal hyperplasia (NIH) [11]. While current procedures aim to remove these blockages, residual material that cannot be fully cleared often leads to recurrent stenosis. These resistant lesions consist mainly of chronic clots (CC) and NIH.
        </p>
        <p>
          A CC becomes firmly attached to the vessel wall over time, composed of cross-linked fibrin, trapped red blood cells, and collagen. This dense, inelastic structure makes it difficult for current devices to remove effectively [12].
        </p>
        <p>
          NIH results from smooth muscle cell proliferation and extracellular matrix buildup triggered by endothelial injury, turbulent flow, and elevated arterial pressures within the AVF circuit. This progressive thickening narrows the vessel lumen and accounts for up to 80% of restenosis cases [13,14] (Appendix A).
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/outflow vein.jpg" alt="Outflow vein - schematic" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 6. Deposition of NIH and CC</em></figcaption>
        </figure>
        <p>
          Together, CC and NIH form tough, wall-adherent lesions that current tools struggle to detach and fully clear, especially in thin, fragile veins. The consequence is residual obstruction, incomplete flow restoration, and a cycle of repeat interventions that ultimately shortens AVF lifespan.
        </p>
      </div>

      <div id="existing-solutions-and-limitations">
        <h3>3.4. Existing solutions and limitations</h3>
        
        <p>
          The first-line treatment for a failing AVF typically involves standard balloon angioplasty to restore blood flow. If this is unsuccessful, cutting balloons or drug-coated balloons are used to score the lesion or reduce restenosis. In more severe cases involving clot formation, thrombectomy devices such as rotational, rheolytic, or aspiration systems are employed, while stents are reserved as a last resort.
        A summary of these devices is presented below, with detailed device-specific analyses provided in Appendix C.
        </p>

        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px;">Device Type</th>
              <th style="border:1px solid #000; padding:10px;">Mechanism of Action</th>
              <th style="border:1px solid #000; padding:10px;">Limitations</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Plain Old Balloon Angioplasty [15]</td>
              <td style="border:1px solid #000; padding:10px;">High-pressure inflation compresses clots and NIH against the vessel wall.</td>
              <td style="border:1px solid #000; padding:10px;">Generates radial compression but no shear or cutting force.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Cutting Balloons [16]</td>
              <td style="border:1px solid #000; padding:10px;">Microsurgical blades create controlled incisions in the intima during inflation.</td>
              <td style="border:1px solid #000; padding:10px;">Produces superficial linear cuts with limited penetration depth.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Drug-Coated Balloons [17]</td>
              <td style="border:1px solid #000; padding:10px;">Balloon coated with antiproliferative drugs (e.g., paclitaxel) to reduce NIH regrowth.</td>
              <td style="border:1px solid #000; padding:10px;">Provides chemical inhibition only, lacks mechanical interaction.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Rotational Thrombectomy [18]</td>
              <td style="border:1px solid #000; padding:10px;">Rotating wire or helix mechanically macerates soft thrombus.</td>
              <td style="border:1px solid #000; padding:10px;">Torque transmission decreases in organized clot but high torque risks venous injury.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Rheolytic Thrombectomy [19]</td>
              <td style="border:1px solid #000; padding:10px;">High-velocity saline jets create a Venturi vacuum to fragment and aspirate thrombus.</td>
              <td style="border:1px solid #000; padding:10px;">Ineffective on dense, adherent lesions and limited shear force.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Aspiration Thrombectomy [20]</td>
              <td style="border:1px solid #000; padding:10px;">Large-bore catheter applies continuous suction to remove thrombus.</td>
              <td style="border:1px solid #000; padding:10px;">Lacks shearing action to detach adherent material. Limited use in small or tortuous vessels.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Stents [21]</td>
              <td style="border:1px solid #000; padding:10px;">Metal mesh scaffold deployed to prevent recoil and maintain vessel patency.</td>
              <td style="border:1px solid #000; padding:10px;">Prone to fracture or migration under repeated cannulation. Unsuitable for AVF biomechanics.</td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:-1em; margin-bottom:1.5em;">Table 2. Current devices and their limitations</p>

        <p>
          Although existing devices are effective at clearing acute, non-adherent clots, none adequately address wall-adherent lesions such as chronic clots and neointimal hyperplasia (NIH). As a result, residual burden remains, contributing to early restenosis and repeat interventions.
        </p>
        <p>
          Their limitations fall into two key domains:
        </p>
        <ol style="margin-left:1.5em; padding-left:0;">
          <li style="margin-bottom:0.75em;">
            <strong>Effectiveness:</strong> Current tools have limited ability to detach and remove chronic, adherent tissue, often leaving behind residual NIH that seeds rapid recurrence.
          </li>
          <li>
            <strong>Safe Navigation and Deliverability:</strong> Most devices struggle to adapt to tortuous, thin-walled AVF anatomy, leading to instability and increased risk of wall injury.
          </li>
        </ol>
        <p>
          These gaps highlight the need for a safe, controllable system capable of reliably detaching and evacuating wall-adherent NIH and chronic clot, capabilities that existing solutions do not provide.
        </p>
        <p>
          Using the product positioning map (Fig. 7), which benchmarks VasCura against current treatment modalities, the proposed system directly addresses these unmet needs by combining a guarded micro-shearing cone to mechanically detach adherent tissue with an integrated debris-capture mechanism to safely remove liberated material without damaging the fragile vein wall.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/product positioning.jpg" alt="Product positioning map comparing VasCura with existing treatment modalities" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 7. Product positioning map</em></figcaption>
        </figure>
      </div>


      <div id="key-insights">
        <h3>3.5. Key Insights</h3>
        <p>
          The fundamental gap lies in a mechanical mismatch between current device actions such as compression, low-shear maceration, suction, or drug diffusion and the biomechanics of AVF lesions, which are fibrotic, wall-adherent, and embedded within thin-walled, tortuous, low-pressure veins.
        </p>
        <p>
          We propose an AVF-specific, vein-safe clearing mechanism that applies controlled micro-shearing and debridement along long venous segments. The design goal is to reduce six-month re-intervention rates by achieving complete, safe, and durable clearance and also a 5&nbsp;mm diameter which is adequate for dialysis by KDOQI guidelines.
        </p>
      </div>

      <div id="need-statement">
        <h3>3.6. Need Statement</h3>
        <p>
          How might we develop a durable solution that enables clinicians to effectively restore and maintain a <strong>&ge;5&nbsp;mm</strong> luminal diameter in arteriovenous fistula (AVF) circuits, by removing chronic clots and neointimal hyperplasia, thereby prolonging access patency and reducing the <strong>6-month</strong> reintervention rate from <strong>50% to 25%</strong>?
        </p>
      </div>

      <div id="value-proposition">
        <h2>4. Value Proposition</h2>
        <p><strong>Built for Better Flow — Clears Tough, Navigates Easy, Lasts Longer.</strong></p>
        <p>
          VasCura is the first AVF-specific device engineered to safely remove tough, wall-adherent chronic clot and neointimal hyperplasia while navigating thin-walled, tortuous veins. Its controlled detachment, micro-fragmentation, and debris evacuation mechanism preserves vessel integrity and restores durable flow.
        </p>
      </div>

      <div id="design-methodology">
        <h2>5. Design methodology</h2>
      </div>

      <div id="jobs-to-be-done-pains-and-gains">
        <h3>5.1. Jobs-to-be-Done, Pains and Gains</h3>
        <p>
          The Jobs-to-be-Done analysis revealed that current AVF interventions fail to maintain durable patency due to inadequate removal of chronic, wall-adherent lesions.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/Jobs to be done.jpg" alt="Jobs-to-be-Done schematic summarising gains, pains, and customer jobs" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 8. Jobs-to-be-Done, Pains and Gains schematic</em></figcaption>
        </figure>
        <p>
          Mapping the Pains, Gains, and Customer Jobs clarified the key performance gaps, allowing us to define both the must-have design requirements essential for clinical success and the nice-to-have features that enhance usability and workflow. These were then translated into quantifiable engineering metrics targeting the core drivers of recurrent stenosis.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/Must haves.jpg" alt="Table summarising must-have design requirements" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 9. Must-have design requirements</em></figcaption>
        </figure>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/good to have.jpg" alt="Table summarising nice-to-have features and benefits" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 10. Nice-to-have features</em></figcaption>
        </figure>
      </div>

      <div id="initial-functional-analysis">
        <h3>5.2. Initial Functional Analysis</h3>
        <p>
          An initial functional analysis was conducted to identify the key inputs and outputs of the VasCura system. 
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/black box.jpg" alt="Black box functional model of VasCura system"
            style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 11. Black
              analysis of VasCura system</em></figcaption>
        </figure>
        <p>
          A functional decomposition was then performed to break down these broad functions into specific sub-functions,
          enabling clearer definition and quantification of performance criteria for each stage of the device’s
          operation.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/fucntional decomposition.jpg" alt="Functional decomposition of VasCura system"
            style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 12. Functional decomposition
              of VasCura sub-systems</em></figcaption>
        </figure>
      </div>

      <div id="design-statement">
        <h2>6. Design Statement</h2>
        <p>Add your design statement here.</p>
      </div>

      <div id="design-specifications">
        <h3>6.1. Design specifications</h3>
        <p>Add your design specifications here.</p>
      </div>

      <div id="concept-generation">
        <h3>6.2. Concept Generation</h3>
        <p>Add your concept generation overview here.</p>
      </div>

      <div id="concept-1">
        <h4>6.2.1 Concept 1</h4>
        <p>Add your concept 1 details here.</p>
      </div>

      <div id="concept-2">
        <h4>6.2.2 Concept 2</h4>
        <p>Add your concept 2 details here.</p>
      </div>

      <div id="concept-3">
        <h4>6.2.3 Concept 3</h4>
        <p>Add your concept 3 details here.</p>
      </div>

      <div id="concept-4">
        <h4>6.2.4 Concept 4</h4>
        <p>Add your concept 4 details here.</p>
      </div>

      <div id="concept-selection">
        <h3>6.3. Concept Selection</h3>
        <p>Add your concept selection here.</p>
      </div>

      <div id="concept-design">
        <h2>7. Concept Design</h2>
        <p>Add your concept design overview here.</p>
      </div>

      <div id="detailed-concept-design">
        <h3>7.1. Detailed Concept Design</h3>
        <p>Add your detailed concept design here.</p>
      </div>

      <div id="prototyping">
        <h2>8. Prototyping</h2>
        <p>Add your prototyping overview here.</p>
      </div>

      <div id="avf-model">
        <h3>8.1. AVF Model</h3>
        <p>Add your AVF model details here.</p>
      </div>

      <div id="thrombosis-stenosis-analogues">
        <h3>8.2. Thrombosis/Stenosis Analogues</h3>
        <p>Add your thrombosis/stenosis analogues here.</p>
      </div>

      <div id="prototyping-bench-testing-models">
        <h3>8.3. Prototyping/Bench testing models</h3>
        <p>Add your prototyping/bench testing models here.</p>
      </div>

      <div id="future-work">
        <h2>9. Future work</h2>
        <p>Add your future work here.</p>
      </div>

    </div>

    <!-- This is an example of how you can use the references component to create references -->
    <div id="references" class="references">
      <sl-divider></sl-divider>
      <h2>References</h2>
      <ul>
        <li>
          Brody, J. E. (2007, December 11). Mental reserves keep brain agile. The New York Times. Retrieved from
          http://www.dowjones.com/factiva/
        </li>
        <li>
          Chamberlin, J., Novotney, A., Packard, E., & Price, M. (2008, May). Enhancing worker well-being: Occupational
          health psychologists convene to share their research on work, stress, and health. Monitor on Psychology,
          39(5), 26-29.
        </li>
        <li>
          Jones, T. J., & Fields, N. (2003). Emotional quotient and personality. E-Journal of Applied Psychology, 2(2),
          38-45. Retrieved from http://ejournalappliedpsyc/index.php/ejap
        </li>
      </ul>
    </div>
  </div>

  <!-- This is the code to display the scroll to top button for ergonomic -->
  <!-- You can leave it as it is, or if you don't like its aesthetics you can also just delete it, -->
  <!-- but it might reduce the user experience. -->
  <sl-button class="scroll-to-top" variant="primary" size="medium" circle onclick="scrollToTop()">
    <sl-icon name="arrow-up" label="Settings"></sl-icon>
  </sl-button>

  <script src="https://unpkg.com/gridjs/dist/gridjs.umd.js"></script>
  <script type="module" src="./components/table-component/table-component.js"></script>
</body>

</html>
